[144] Addus HomeCare Corp. SEC Filing

Rhea-AI Filing Summary

Addus HomeCare Corp. (ADUS) Form 144 notifies a proposed sale of 25,000 common shares by an identified seller through Morgan Stanley Smith Barney on Nasdaq with an aggregate market value of $2,895,722.50. The shares were acquired and are proposed to be sold on 09/02/2025 following a stock option exercise paid in cash. The filer also discloses a prior sale by the same person of 25,000 shares on 08/20/2025 for gross proceeds of $2,873,862.50. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.

Insights

Financial Analyst

TL;DR: Insider executed and intends to sell 25,000 shares acquired via option exercise, generating roughly $2.9M in market value.

The filing shows a routine liquidity event: a stock option exercise and immediate/proposed disposition of the resulting shares through a broker on Nasdaq. Transaction dates and gross proceeds for a recent sale are disclosed, which helps transparency into insider activity. This does not provide performance metrics or indicate company operational change; its investor relevance is limited to insider selling activity and timing.

Corporate Governance Expert

TL;DR: Form 144 documents a disclosed insider sale following option exercise, with required signer attesting no undisclosed material information.

The document fulfills Rule 144 disclosure requirements by identifying the class, broker, quantity, acquisition method, and sale dates. The signer’s attestation about lack of undisclosed material information is included as required. No additional governance actions, trading plan dates, or restrictions are provided in the filing itself.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	2895722.50	18407239	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Stock Option Exercise	Issuer			25000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DIRK ALLISON 6303 Cowboys Way, Suite 600 Frisco TX 75034	Common	08/20/2025	25000	2873862.50

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the Form 144 for ADUS report being sold?

The filing reports proposed sale of 25,000 common shares of Addus HomeCare Corp. on Nasdaq.

Who is the broker handling the proposed sale in the ADUS Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.

When were the shares acquired and by what method according to the filing?

The shares were acquired on 09/02/2025 via a stock option exercise and paid in cash.

What were the aggregate market value and gross proceeds disclosed?

The proposed sale shows an aggregate market value of $2,895,722.50; a prior sale on 08/20/2025 generated gross proceeds of $2,873,862.50.

Does the filing state whether the seller knows of any undisclosed material information?

Yes. The signer represents that they do not know any material adverse information